Johnson & Johnson (JNJ): I Counted 15 Separate Surprises," Says Jim Cramer

We recently published 10 Stocks Jim Cramer Discussed As He Shared Key Insights From Morgan Stanley’s CEO. Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed.

Johnson & Johnson (NYSE:JNJ)’s shares are up by 5% since its latest earnings report, which saw it post $23.7 billion in sales to beat analyst estimates of $22.8 billion. Crucially, the shares were helped by Johnson & Johnson (NYSE:JNJ)’s midpoint annual revenue guidance, which the firm raised by $2 billion, and by its midpoint full year EPS of $10.85, which marked a 25-cent jump. Cramer was impressed by Johnson & Johnson (NYSE:JNJ)’s results and shared that the firm surprised on 15 different metrics:

“And then yesterday, unheard and unsung, but we’re going to change that. Johnson & Johnson. Johnson & Johnson delivered a quarter, I counted 15 separate surprises. . .15 different things. That they beat on. All sorts of different metrics.”

Previously, he discussed Johnson & Johnson (NYSE:JNJ)’s prospects ahead of the earnings release:

“Johnson & Johnson kicks off pharma earnings season on Wednesday, and I think once again, the company will not be rewarded for its consistency or its originality because there’s still the sort of the talc lawsuits hanging over it. I don’t mind JNJ fighting the plaintiff’s part, but it sure puts a damper on the stock.”

While we acknowledge the potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.